Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: A retrospective cohort study

Grace Qian, Xiaosong Wang, Naomi J. Patel, Yumeko Kawano, Xiaoqing Fu, Claire Cook, Kathleen M.m. Vanni, Emily Kowalski, Emily Banasiak, Katarina J Bade, Shruthi Srivatsan, Zachary K Williams, Derrick J. Todd, Michael E. Weinblatt, Zachary S. Wallace, Jeffrey A. Sparks

Abstract

These results should encourage clinicians to prescribe and SARD patients to seek prompt outpatient COVID-19 treatment. This research provides an early estimate of the prevalence of COVID-19 rebound after oral outpatient treatment to quantify this risk to clinicians and SARD patients and encourage future research.

Introduction

Patients with systemic autoimmune rheumatic diseases (SARDs), such as rheumatoid arthritis or systemic lupus erythematosus, represent a uniquely vulnerable population in the context of the COVID-19 pandemic. The intersection of their underlying autoimmune conditions and the immunosuppressive therapies required to manage them often results in impaired vaccine efficacy and a heightened risk for severe infection.

While clinical trials for oral antivirals like nirmatrelvir/ritonavir (Paxlovid) and molnupiravir demonstrated significant efficacy in reducing hospitalization and death, these trials were primarily conducted in unvaccinated populations prior to the dominance of the Omicron variant. Consequently, a significant data gap emerged regarding the real-world effectiveness of these treatments for high-risk, highly vaccinated SARD patients. Furthermore, anecdotal reports of "COVID-19 rebound"—the recurrence of symptoms or positive tests after initial recovery—necessitated a formal quantification of this risk within the SARD community.

Methods

This retrospective cohort study utilized data from the Mass General Brigham (MGB) healthcare system in Boston, analyzing 704 SARD patients who contracted COVID-19 between January and May 2022, a period coinciding with the Omicron surge.

Case Identification and Validation

Patients were identified through electronic health record (EHR) queries for positive SARS-CoV-2 PCR or antigen tests. To ensure the accuracy of the SARD cohort, researchers employed a validated administrative data algorithm requiring specific diagnosis codes and concurrent immunomodulator prescriptions, a method previously shown to have a 90% positive predictive value.

Data Collection

Unlike many large-scale database studies, this research involved a rigorous manual review of medical records. This allowed the team to confirm outpatient treatment status, verify vaccination history, and identify documented cases of COVID-19 rebound. The primary outcome was a composite of COVID-19-related hospitalization or death within 30 days of the initial infection.

Statistical Analysis

The researchers utilized multivariable logistic regression to calculate adjusted odds ratios (aOR), controlling for potential confounders including age, the Charlson Comorbidity Index (CCI), kidney function (eGFR), and race.

Results

Clinical Outcomes and Treatment Efficacy

The study found that outpatient treatment provided a massive additional layer of protection, even in a population where 96% of patients were vaccinated. The primary outcome of hospitalization or death occurred in only 2.1% of treated patients, compared to 17.6% of untreated patients.

After adjusting for confounders, the use of any outpatient treatment was associated with an 88% reduction in the risk of severe outcomes (aOR 0.12; 95% CI 0.05 to 0.25). When analyzing specific treatments:

  • Nirmatrelvir/ritonavir (Paxlovid): aOR 0.08
  • Monoclonal antibodies: aOR 0.20

Secondary analyses suggested no statistically significant difference in efficacy between Paxlovid and monoclonal antibodies, providing clinicians with flexibility based on patient-specific contraindications, such as renal function.

The Phenomenon of COVID-19 Rebound

Of the 318 patients who received oral antiviral treatment, 25 (8%) experienced a documented COVID-19 rebound. The study defined rebound strictly as a documented negative test followed by a new positive test and symptom recurrence within the EHR. Notably, none of the rebound cases in this cohort resulted in subsequent hospitalization or death, suggesting that while rebound is a clinical reality, it did not lead to severe disease in this study period.

Discussion

Real-World Implications

The findings underscore that vaccination alone does not represent the ceiling of protection for immunocompromised individuals. The shift in clinical practice observed during the study—where treatment rates rose from 35% to 65%—reflects a growing recognition of the benefits of early intervention. The 8% rebound rate likely represents a "floor" estimate, as patients who did not seek follow-up testing within the MGB system would not have been captured.

Limitations

Several limitations must be considered. The study was conducted within a single geographic region with high baseline vaccination rates, which may limit generalizability to other populations. Additionally, selection bias may exist, as patients who proactively seek testing and treatment might differ from those who manage the illness at home. Finally, the strict EHR-based definition of rebound likely missed cases that were not formally reported to a provider.

Conclusion

Outpatient treatments for COVID-19 are highly effective at preventing severe outcomes in patients with SARDs, regardless of vaccination status. While COVID-19 rebound occurs in approximately 1 in 12 patients, it does not appear to be associated with a high risk of subsequent hospitalization. Clinicians should continue to prioritize prompt outpatient treatment for this high-risk population. Future prospective research is needed to determine if extended treatment courses could further reduce the risk of rebound in severely immunosuppressed patients.

Summary updated

Abstract

These results should encourage clinicians to prescribe and SARD patients to seek prompt outpatient COVID-19 treatment.This research provides an early estimate of the prevalence of COVID-19 rebound after oral outpatient treatment to quantify this risk to clinicians and SARD patients and encourage future research.
BibTeX
@inproceedings{qian2023outcomes,
  author = {Grace Qian and Xiaosong Wang and Naomi J. Patel and Yumeko Kawano and Xiaoqing Fu and Claire Cook and Kathleen M.M. Vanni and Emily Kowalski and Emily Banasiak and Katarina J Bade and Shruthi Srivatsan and Zachary K Williams and Derrick J. Todd and Michael E. Weinblatt and Zachary S. Wallace and Jeffrey A. Sparks},
  title = {{Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: A retrospective cohort study}},
  booktitle = {The Lancet Rheumatology},
  year = {2023},
  doi = {10.1016/s2665-9913(23)00006-1},
}
Figure